SBRT2015

Matthias Guckenberger - DEGRO 2015

C O N C L U S I O N S



Clear dose effect relationship in stage I NSCLC and

pulmonary metastases



Dose explains well high rates of local tumor control



Dose-response not different between primary NSCLC

and pulmonary metastases



PTV encompassing dose >100Gy BED achieves

>90% TCP



Total dose adapted to competing risk of death /

progression



Fractionation adapted to risk of OAR toxicity

29.08.2015